Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Completed 4Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 3Lymphoid 1Classical hematology 1

Conditions

Arthritis, Rheumatoid 8Psoriasis 7Lymphoma, Follicular 4Leukemia 4Myelodysplastic Syndromes 3Asthma 3Vasculitis 2Respiratory Distress Syndrome 2Recurrence 2Pneumonia 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Inflammation 2Granulomatosis with Polyangiitis 2Bronchiolitis Obliterans 2Arthritis, Psoriatic 2Arthritis, Juvenile 2Wilms Tumor 1Uveitis 1Temporomandibular Joint Disorders 1Spondylitis, Ankylosing 1Spondylarthritis 1Pruritus 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plaque, Amyloid 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasms 1Metabolic Syndrome 1

Interventions

Cyclophosphamide 227Cytarabine 194fludarabine phosphate 138Methotrexate 132Filgrastim 127Busulfan 103Etoposide 99Peripheral Blood Stem Cell Transplantation 91Rituximab 81fludarabine 77Radiotherapy 77Vincristine 74Daunorubicin 68Antilymphocyte Serum 65Cyclosporine 63Dexamethasone 61Tacrolimus 56Mycophenolic Acid 53Melphalan 52Imatinib Mesylate 50Granulocyte Colony-Stimulating Factor 50Mercaptopurine 46Whole-Body Irradiation 45Idarubicin 43sargramostim 42Methylprednisolone 42Doxorubicin 41Flow Cytometry 40Prednisone 39Clofarabine 39

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Leukemia × Etanercept × Clear all
NCT00201682 2017-02-08

Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Completed
36 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00093366 2011-11-30

Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes

Fred Hutchinson Cancer Center

Phase 1/2 Completed
32 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00217386 2010-09-15

Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes

Fred Hutchinson Cancer Center

Phase 2 Completed
30 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00005853 2010-04-02

Biological Therapy in Treating Patients With Myelodysplastic Syndrome

Fred Hutchinson Cancer Center

Phase 2 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡